A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium
Year: 2008
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: L. R. Silverman, A. Verma, R. Odchimar-Reissig, A. Cozza, V. Najfeld, J. D. Licht, J. A. Zwiebel
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2277074589